This is consistent with the idea that KIR2DL1 has minimal peptide preferences when binding HLA-C*05:01, including P2-GG that contains no sides chains at p7p8 [6, 8]
What human evidence supports each peptide for that goal
Lindsay Tyler: Well, it's certainly been remarkable to watch this financing theme take shape in real time, and the next chapter sounds like it could be even more interesting to follow
Jiang C, et al
Forward-looking statements generally relate to future events or the Companys future financial or operating performance and may include, without limitation, statements regarding the anticipated launch, availability, distribution, commercialization and potential adoption of Forzet , the expected benefits of the product, the Companys plans to integrate Forzet into its pharmacy network and telehealth offerings, the development and expansion of the Companys direct-to-consumer initiatives, and the potential growth of the GLP-1 agonist market